Silexion Therapeutics CorpSLXNEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and immunological diseases. It serves North American and global healthcare markets, with R&D focused on novel biologic candidates addressing unmet patient medical needs.
SLXN Q4 FY2025 Key Financial Metrics
Revenue
$70.0K
Gross Profit
N/A
Operating Profit
$-4.4M
Net Profit
$-4.4M
Gross Margin
N/A
Operating Margin
-6294.3%
Net Margin
-6302.9%
YoY Growth
N/A
EPS
$1.50
Silexion Therapeutics Corp Q4 FY2025 Financial Summary
Silexion Therapeutics Corp reported revenue of $70.0K for Q4 FY2025, with a net profit of $-4.4M (-6302.9% margin).
Key Financial Metrics
| Total Revenue | $70.0K |
|---|---|
| Net Profit | $-4.4M |
| Gross Margin | N/A |
| Operating Margin | -6294.3% |
| Report Period | Q4 FY2025 |
Silexion Therapeutics Corp Quarterly Revenue & Net Profit History
Silexion Therapeutics Corp results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $70.0K | — | $-4.4M | -6302.9% |
| Q3 FY2025 | $39.0K | — | $-3.3M | -8364.1% |
| Q2 FY2025 | $44.0K | +633.3% | $-2.5M | -5688.6% |
| Q3 FY2024 | $0 | — | $-11.9M | N/A |
Income Statement
| Q3 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $44000 | $39000 | $70000 |
| YoY Growth | N/A | 633.3% | N/A | N/A |
Balance Sheet
| Q3 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $3.1M | $5.8M | $11.6M | $7.2M |
| Liabilities | $7.7M | $5.7M | $4.6M | $4.6M |
| Equity | $-4.6M | $120000 | $7.0M | $2.6M |
Cash Flow
| Q3 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-2.7M | $-2.5M | $-2.8M | $-3.0M |